Clinical Trial Update: Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing single-agent pembrolizumab to single-agent chemotherapy in metastatic triple-negative breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Triple Negative Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-05-04